The pharmaceutical industry views Brexit as a ‘done deal’

Drug pricing and reimbursement continue to be the leading concern for the pharmaceutical industry in 2020, according to GlobalData.

In its annual outlook report, titled ‘The State of the Biopharmaceutical Industry – 2020’, the data and analytics company revealed that 49 per cent of global industry survey respondents expect drug pricing and reimbursement constraints to create the greatest negative impact on the pharmaceutical industry this year.

Brexit ranked lowest in the study as the industry views it as a ‘done deal’.

This was followed by the political divide in the US with 14 per cent of the respondents.

GlobalData predicts drug pricing pressure from regulators and payers to remain the leading impediment to industry growth in 2020 along with aggressive negotiation tactics to drive down drug prices.

Bonnie Bain, Global Head of Pharma at GlobalData, said: “It is not surprising that drug pricing and reimbursement constraints remain the number one concern for the industry, especially since 2020 kicked off with drug companies in the US again raising prices for several hundred drugs.”

If you want to share your stories and/or experiences with us, please send an email to [email protected]